SCHEMBL1714404

SCHEMBL1714404

CC1=NC(=Cc2c[nH]c3ncccc23)C(=O)N1Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.45
CHEK1 O14757 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
HASPIN Q8TF76 4/20 0.43
CCNT1 O60563 2/20 0.43
CDK9 P50750 2/20 0.43
MET P08581 1/20 0.42
ADORA2A P29274 1/20 0.40
CDC7 O00311 3/20 0.39
LATS1 O95835 1/20 0.38
LATS2 Q9NRM7 1/20 0.38
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714402 1.00 AKR1B1 (0.45) AKR1B1CHEK1KMT2AKDM4EALDH1A1
SCHEMBL1714107 0.86 KMT2A (0.47) AKR1B1CHEK1KMT2AHASPINCCNT1
SCHEMBL1714105 0.86 KMT2A (0.47) AKR1B1CHEK1KMT2AHASPINCCNT1
SCHEMBL1713472 0.81 KMT2A (0.51) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713471 0.81 KMT2A (0.51) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713544 0.79 CDC7 (0.47) AKR1B1CHEK1KMT2AHASPINCCNT1
SCHEMBL1713546 0.79 CDC7 (0.47) AKR1B1CHEK1KMT2AHASPINCCNT1
SCHEMBL13676711 0.79 MET (0.47) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713841 0.78 KMT2A (0.48) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713843 0.78 KMT2A (0.48) CHEK1KMT2AHASPINCCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 AKR1B1 3092/4885CHEK1 17/4885KMT2A 3256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.